Table 3.

Pairwise meta-analysis of VEGFR-TKIs’ serious cardiovascular event (grade 3 or high)

Direct compare	Study number	Total sample	Odds ratio (95% CI)	Method	Heterogeneity
Cabozantinib vs placebo	2	1027	10.56 (2.39,46.58)	M–H random	I2 = 61% (P = 0.11)
Suntinib vs placebo	4	1282	6.33 (2.54,15.78)	M–H random	I2 = 16% (P = 0.31)
Sorafenib vs placebo	9	4732	4.97 (3.25,7.59)	M–H random	I2 = 0% (P = 0.69)
Regorafenib vs placebo	6	2050	4.69 (2.29,9.60)	M–H random	I2 = 52% (P = 0.07)
Vandetanib vs placebo	5	1619	8.29 (3.74,18.40)	M–H random	I2 = 0% (P = 0.47)
Nintedanib vs placebo	2	848	6.35 (2.18,18.52)	M–H random	I2 = 0% (P = 0.64)
Pazopanib vs placebo	5	2038	7.03 (4.85,10.18)	M–H random	I2 = 0% (P = 0.89)
Axitinib vs sorafenib	2	999	1.79 (0.10,32.69)	M–H random	I2 = 93% (P = 0.00001)
Nintedanib vs sorafenib	2	188	1.09 (0.29,4.11)	M–H random	I2 = 0% (P = 0.82)